commercialization

Aduro Clean Technologies to present investor updates on pilot operations and Hydrochemolytic™ technology commercialization at the March 2026 ROTH Conference in California.

BioRestorative Therapies will exhibit at Be+Well Beauty and Wellness Show in NYC (March 8-10, 2026) to advance its BioCosmeceutical platform commercialization.

Pony AI will report Q4 and FY2025 results March 26, 2026. Company achieves Gen-7 robotaxi unit economics breakeven in Shenzhen and records strong holiday orders.

Archer Aviation's profitability depends on 2026 FAA certification of its eVTOL aircraft. The company has $1.6B cash but faces regulatory uncertainty risks.

Ideal Power raised $14M to commercialize its B-TRAN semiconductor technology, funding customer design-ins, partnerships, and production infrastructure.

General Fusion merges with SPAC to go public via Nasdaq under ticker GFUZ, valuing the fusion energy company at $1 billion with closing expected mid-2026.

Kyverna appoints two biotech executives to its board ahead of cell therapy commercialization. New directors bring expertise from Beam Therapeutics and Karuna Therapeutics.

Beam Therapeutics secures $500M credit facility from Sixth Street Partners to fund commercial launch of its sickle cell therapy, with payments tied to clinical and regulatory milestones.

Ideal Power raises $14M through mixed equity financing to accelerate commercialization of its B-TRAN semiconductor technology and expand customer design-ins.

Uber launched autonomous vehicle division with $100M+ charging investment, but shares fell 4.49%. Analysts maintain Buy ratings despite market skepticism.

ImmunityBio launches 85-person European sales team for bladder cancer drug Anktiva across 30 countries, partnering with Accord Healthcare and establishing an Irish subsidiary for distribution.

Small-cap biotech and industrial firms rallied on acquisitions and patent filings. Interactive Strength surged 40% after acquiring Ergatta, while biotech companies advanced through strategic initiatives and IP development.

Quantum Computing Inc. faces scrutiny over its $1.9B valuation versus just $546K revenue, with analysts citing cash burn concerns and questions about management credibility.

Psyence BioMed secures pharmaceutical-grade psychedelic supply through put option deal with PsyLabs, ensuring reliable access while maintaining liquidity for clinical development.

Coherus Oncology raises $50.1M via stock offering to fund commercial expansion of LOQTORZI and advance oncology pipeline development programs.